May 6th 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Behind the FDA Approval: Belzutifan for VHL-Associated Renal Cell Carcinoma
November 23rd 2021In an interview with Targeted Oncology, Eric Jonasch, MD, discussed the impact belzutifan has had on the VHL-assocaited renal cell carcinoma space, along with unmet clinical needs the agent is addressing.
Read More
Post-Hoc Analysis Shows Adverse Events With First-line Nivolumab Plus Cabozantinib Are Manageable
November 18th 2021In a post-hoc analysis of the CheckMate 9ER trial, researchers found that, along with additional efficacy benefits, the combination of nivolumab plus cabozantinib had manageable adverse events.
Read More
FDA Approves Adjuvant Pembrolizumab for Renal Cell Carcinoma
November 18th 2021The FDA has approved adjuvant pembrolizumab for the treatment of renal cell carcinoma with an intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.
Read More
Modified Ipilimumab Dosing in Ipilimumab/Nivolumab Combo Improves Toxicity in Advanced RCC
November 13th 2021A significant reduction in the number of patients experiencing grade 3 or 4 toxicity was observed with modified dosing as ipilimumab combine with nivolumab in patients with advanced renal cell carcinoma.
Read More
Efficacy and Safety Assessment of Frontline Lenvatinib Plus Pembrolizumab Underway for nccRCC
November 6th 2021The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.
Read More
Precision Medicine According to Histologic Subtype in Renal Cell Carcinoma
November 6th 2021During a presentation at the 2021 International Kidney Cancer Symposium, Bradley McGregor, MD, discussed analyses of outcomes based on histology in major RCC clinical trials, and how this approach will shape the future of treatment.
Read More
New Research Warrants Use of TKI/ICI Salvage Therapy in Metastatic RCC
November 2nd 2021Sarah P. Psutka, MD, discusses the key findings of a retrospective study of the efficacy of Immune checkpoint inhibitor plus tyrosine kinase inhibitor as any-line treatment for patients with renal cell carcinoma.
Watch
Study Identifies Three New Independent Prognostic Indicators of RFS in Renal Cell Carcinoma
October 29th 2021Retrospective data suggest that perinephric fat invasion, sarcomatoid or rhabdoid component, and necrosis are independent prognostic indicators of recurrence-free survival in renal cell carcinoma.
Read More
DFS Benefit of Adjuvant Pembrolizumab Seen Across RCC Subgroups
September 14th 2021An impressive disease-free survival benefit was seen in patients with clear cell renal cell carcinoma with pembrolizumab as an adjuvant therapy following nephrectomy compared with placebo. This improvement was observed across subgroups.
Read More
Efficacy of Nivolumab/Ipilimumab May Change Timing of Cytoreductive Nephrectomy in Advanced RCC
September 10th 2021Roughly 50% of patients with clear cell renal cell carcinoma responded to the combination of nivolumab plus ipilimumab in a Japanese study, and varied responses occurred in those with nonclear cell histology.
Read More